Bioatividade da quinoxalina 1,4-dióxido e seus derivados

O objetivo deste estudo consiste em avaliar a atividade antimicrobiana da quinoxalina 1,4-dióxido e alguns dos seus derivados em estirpes bacterianas e leveduras. Os compostos estudados foram a quinoxalina 1,4-dióxido (QNX), 2-metilquinoxalina-1,4-dióxido (2MQNX), 2-metil-3-Benzoilquinoxalina-1,4-dióxido (2M3BenzoilQNX), 2-metil-3-benzilquinoxalina-1,4-dióxido (2M3BQNX), 2-amino-3-cianoquinoxalina-1,4-dióxido (2A3CQNX), 3-metil-2-quinoxalinacarboxamida-1,4-dióxido (3M2QNXC), 2-hidroxifenazina–N-dióxido (2HF) e 3-metil-N-(2-metilphenil)quinoxalinacarboxamida-1,4-dioxido (3MN(2MF)QNXC). Os modelos procariotas selecionados para este estudo foram o Staphylococcus aureus ATCC 6538, Staphylococcus aureus ATCC 6538P, Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, Escherichia coli S3R9, Escherichia coli S3R22, Escherichia coli TEM CTX-M9, Escherichia coli TEM-1, Escherichia coli AmpC MOX-2, Escherichia coli CTX-M2 e Escherichia coli CTX-M9. A Candida albicans ATCC 10231 e a Saccharomyces cerevisiae PYCC 4072 constituíram os modelos eucariotas deste estudo. Para os compostos químicos que apresentem atividade pelo método de difusão em disco, será determinada a Concentração Mínima Inibitória (CMI), bem como a viabilidade e o crescimento (na presença e na ausência dos compostos químicos). Os resultados deste estudo mostram atividade antimicrobiana para a maioria dos compostos estudados em todos os modelos procariotas Gram negativos, à exceção da E.coli CTX-M2 e CTX-M9 e nenhuma atividade nos modelos eucariotas. O estudo da viabilidade/curvas de morte em bactérias e num modelo eucariota (S.cerevisiae) sugerem que alguns destes compostos constituem potenciais drogas para a quimioterapia antibacteriana.

Antimicrobial activity of quinoxaline 1,4-dioxide and three derivatives

O presente trabalho descreve o estudo da actividad e antimicrobiana de quarto derivados da quinoxalina N,N-dióxido: quinoxalina 1,4-dióxido, 2-metilquinoxalina 1,4- dióxido, 6-cloro-2,3-dimetilquinoxalina 1,4-dióxido e 3-benzoil-2-metilquinoxalina 1,4- dióxido contra as estirpes bacterianas Geobacillus stearothermophilus ATCC 10149, Escherichia coli ATCC 25922, Escherichia coli HB101, Escherichia coli (blaTEM, blaCTX-M) e Salmonella (blaCTX-M), assim como contra a estirpe de levedura Saccharomyces cerevisiae PYCC 4072. A determinação da concentração mínima inibitória (MIC) foi realizada pelo método de diluição. Os valores de MIC’s foram estimados para cada composto e estirpe. Os resultados obtidos sugerem potenciais novas drogas para quimioterapia.

Anti-pneumoscystis carinni activitiy of primaquine imidazolidin-4-ones

Pneumocystis pneumonia (PCP) is one of the most frequent causes of mortality among HIV-infected patients. Primaquine (PQ) is an antimalarial 8-aminoquinoline effective against PCP when given in combination with clindamycin. This has drawn the attention of Medicinal Chemists towards the anti-PCP activity of 8-aminoquinolines, not only confined to those exhibiting antimalarial activity [1]. It is thought that anti-PCP 8-aminoquinolines exert their anti-PCP activity by acting on the electronic transport and redox system of the P. carinii pathogen [1]. Recently, our research group has been developing imidazolidin-4-one derivatives of PQ (Scheme 1), targeting novel compounds with improved therapeutic action, namely, higher resistance to metabolic inactivation, lower toxicity and equal or higher antimalarial activity than that of the parent drug [2,3]. These imidazolidin-4-ones were seen to block the transmission of rodent malaria, caused by Plasmodium berghei on BalbC mice, to the mosquito vector Anopheles stephensi [3]. The anti-PCP activity of our PQ derivatives is now under study and preliminary in vitro assays [4] show that some of the compounds exhibit slight to moderate activity after a 72 h incubation period against P. carinii. In one case, the IC50 was comparable to that of parent PQ. Both these studies and forthcoming results from ongoing biological assays will be presented and discussed.

A survey on e-learning content standardization

eLearning has been evolved in a gradual and consistent way. Along with this evolution several specialized and disparate systems appeared to fulfill the needs of teachers and students such as repositories of learning objects, intelligent tutors, or automatic evaluators. This heterogeneity poses issues that are necessary to address in order to promote interoperability among systems. Based on this fact, the standardization of content takes a leading role in the eLearning realm. This article presents a survey on current eLearning content standards. It gathers information on the most emergent standards and categorizes them according three distinct facets: metadata, content packaging and educational design.